Zobrazeno 1 - 7 of 7 pro vyhledávání: '"Danilo Giffoni de Mello Morais Mata"'
1
Akademický článek
The Omission of Anthracycline Chemotherapy in Women with Early HER2-Negative Breast Cancer—A Systematic Review and Meta-Analysis
Autor: Danilo Giffoni de Mello Morais Mata, Mary-Beth Rush, Megan Smith-Uffen, Jawaid Younus, Ana Elisa Lohmann, Maureen Trudeau, Rebecca L. Morgan
Publikováno v: Current Oncology, Vol 31, Iss 8, Pp 4486-4506 (2024)
Background: Anthracycline-taxane is the standard chemotherapy strategy for treating high-risk early breast cancer despite the potentially life-threatening adverse events caused by anthracyclines. Commonly, the combination of docetaxel and cyclophosph
Externí odkaz: https://doaj.org/article/61091beb6ad8455eaf7e5d113d0d0827
Zobrazit plný text záznamu
2
Akademický článek
Appraising Adjuvant Endocrine Therapy in Hormone Receptor Positive HER2-Negative Breast Cancer—A Literature Review
Autor: Danilo Giffoni de Mello Morais Mata, Carlos Amir Carmona, Andrea Eisen, Maureen Trudeau
Publikováno v: Current Oncology, Vol 29, Iss 7, Pp 4956-4969 (2022)
Background: Approximately 75% of breast cancer (BC) is associated with luminal differentiation expressing endocrine receptors (ER). For ER+ HER2− tumors, adjuvant endocrine therapy (ET) is the cornerstone treatment. Although relapse events steadily
Externí odkaz: https://doaj.org/article/19d50871fa534dc3958ed5f056155838
Zobrazit plný text záznamu
4
Predicting treatment toxicity in older adults with cancer
Autor: Tyler R. Chesney, Ines B. Menjak, Kristen R. Haase, Danilo Giffoni de Mello Morais Mata
Publikováno v: Current opinion in supportive and palliative care. 15(1)
Purpose of review To provide an overview of the recent advancements in predicting toxicity associated with cancer treatment in older patients. Recent findings Various screening tools and validated risk calculators have been shown to help predict toxi
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e0c8491c5d61dce44b21ee708e49fa6
https://pubmed.ncbi.nlm.nih.gov/33399394
Zobrazit plný text záznamu
5
Overall survival comparison in patients with and without brain metastases treated with osimertinib for metastatic EGFR mutation positive non-small cell lung cancer (NSCLC)
Autor: Carlos Amir Carmona Gonzalez, Alia Thawer, Mark A. Doherty, Ines B. Menjak, Maria Romero, Danilo Giffoni de Mello Morais Mata
Publikováno v: Journal of Clinical Oncology. 39:e21216-e21216
e21216 Background: With the development of Epidermal Growth factor receptor (EGFR) tyrosine kinase inhibitors such as Osimertinib, the landscape of lung cancer treatment and outcomes has changed. We aimed to describe the outcomes of patients treated
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a7da896fb8fdbad4d9407a4b1a68ebc6
https://doi.org/10.1200/jco.2021.39.15_suppl.e21216
Zobrazit plný text záznamu
6
Sequencing of systemic therapies in advanced NSCLC with MET exon 14 skipping mutation: A multicenter experience
Autor: Brandon S. Sheffield, Natasha B. Leighl, Andrea S. Fung, Parneet Cheema, David M. Hwang, Danilo Giffoni de Mello Morais Mata, Susanna Y. Cheng, Kirstin Perdrizet, Frances A. Shepherd, Penelope A. Bradbury, Adrian G. Sacher, S. Lau, Geoffrey Liu, Ming-Sound Tsao
Publikováno v: Journal of Clinical Oncology. 39:e21123-e21123
e21123 Background: The treatment landscape for patients with metastatic non-small cell lung cancer (mNSCLC) with a MET exon 14 skipping mutation ( MET ex14) is rapidly changing, with recent approvals of MET selective tyrosine kinase inhibitors (TKIs)
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6739770d3ec0768652900b468aae0f6f
https://doi.org/10.1200/jco.2021.39.15_suppl.e21123
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje